Indivior’s Opvee (nalmefene) Nasal Spray Receives the US FDA’s Approval for Treatment of Opioid Overdose
Shots:
- The US FDA has approved Opvee nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged ≥12yrs. Opvee is expected to be available in Q4’23
- The approval was based on the PD study evaluating the effect of Opvee on remifentanil-induced respiratory depression incl. 61 opioid-experienced, non-dependent study patients
- The results showed a fast onset of reversal of respiratory depression b/w 2.5 and 5min. & full recovery was seen as early as 5min. after administrating Opvee. Opvee is supplied in a ready-to-use, unit-dose nasal spray device that delivers 2.7mg of nalmefene
Ref: PR Newswire | Image: Indivior
Related News:- Indivior to Acquire Opiant Pharmaceuticals for ~$145M
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
